nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—ABCG2—Cladribine—multiple sclerosis	0.058	0.152	CbGbCtD
Pazopanib—ABCG2—Mitoxantrone—multiple sclerosis	0.0423	0.111	CbGbCtD
Pazopanib—CYP2D6—Fingolimod—multiple sclerosis	0.0306	0.0803	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—multiple sclerosis	0.0222	0.0582	CbGbCtD
Pazopanib—ABCG2—Dexamethasone—multiple sclerosis	0.022	0.0576	CbGbCtD
Pazopanib—ABCB1—Methylprednisolone—multiple sclerosis	0.0209	0.0549	CbGbCtD
Pazopanib—CYP3A4—Fingolimod—multiple sclerosis	0.0195	0.051	CbGbCtD
Pazopanib—ABCG2—Methotrexate—multiple sclerosis	0.0176	0.0463	CbGbCtD
Pazopanib—ABCB1—Mitoxantrone—multiple sclerosis	0.0153	0.04	CbGbCtD
Pazopanib—ABCB1—Betamethasone—multiple sclerosis	0.0136	0.0357	CbGbCtD
Pazopanib—ABCB1—Prednisolone—multiple sclerosis	0.0134	0.0352	CbGbCtD
Pazopanib—ABCB1—Prednisone—multiple sclerosis	0.0127	0.0333	CbGbCtD
Pazopanib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0125	0.0329	CbGbCtD
Pazopanib—CYP2C8—Dexamethasone—multiple sclerosis	0.0117	0.0307	CbGbCtD
Pazopanib—CYP3A4—Triamcinolone—multiple sclerosis	0.0095	0.0249	CbGbCtD
Pazopanib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00915	0.024	CbGbCtD
Pazopanib—CYP3A4—Betamethasone—multiple sclerosis	0.00815	0.0214	CbGbCtD
Pazopanib—CYP3A4—Prednisolone—multiple sclerosis	0.00805	0.0211	CbGbCtD
Pazopanib—ABCB1—Dexamethasone—multiple sclerosis	0.00792	0.0208	CbGbCtD
Pazopanib—CYP3A4—Prednisone—multiple sclerosis	0.0076	0.0199	CbGbCtD
Pazopanib—CYP2D6—Dexamethasone—multiple sclerosis	0.00746	0.0196	CbGbCtD
Pazopanib—ABCB1—Methotrexate—multiple sclerosis	0.00636	0.0167	CbGbCtD
Pazopanib—BMPR1B—peripheral nervous system—multiple sclerosis	0.00521	0.0359	CbGeAlD
Pazopanib—CYP3A4—Dexamethasone—multiple sclerosis	0.00474	0.0124	CbGbCtD
Pazopanib—FGF1—nerve—multiple sclerosis	0.00284	0.0196	CbGeAlD
Pazopanib—SH2B3—retina—multiple sclerosis	0.00203	0.014	CbGeAlD
Pazopanib—MAP3K9—midbrain—multiple sclerosis	0.0019	0.0131	CbGeAlD
Pazopanib—MAP3K9—nervous system—multiple sclerosis	0.00156	0.0108	CbGeAlD
Pazopanib—TAOK1—medulla oblongata—multiple sclerosis	0.00156	0.0107	CbGeAlD
Pazopanib—MAP3K9—central nervous system—multiple sclerosis	0.0015	0.0104	CbGeAlD
Pazopanib—MAP3K9—cerebellum—multiple sclerosis	0.00147	0.0101	CbGeAlD
Pazopanib—SH2B3—medulla oblongata—multiple sclerosis	0.00147	0.0101	CbGeAlD
Pazopanib—TAOK1—midbrain—multiple sclerosis	0.00142	0.00982	CbGeAlD
Pazopanib—TAOK1—spinal cord—multiple sclerosis	0.00139	0.00958	CbGeAlD
Pazopanib—SH2B3—midbrain—multiple sclerosis	0.00134	0.00924	CbGeAlD
Pazopanib—PIP4K2C—retina—multiple sclerosis	0.00132	0.00909	CbGeAlD
Pazopanib—SH2B3—spinal cord—multiple sclerosis	0.00131	0.00902	CbGeAlD
Pazopanib—FGFR3—medulla oblongata—multiple sclerosis	0.00123	0.00847	CbGeAlD
Pazopanib—RIOK2—medulla oblongata—multiple sclerosis	0.00123	0.00847	CbGeAlD
Pazopanib—FGF1—brainstem—multiple sclerosis	0.00122	0.00842	CbGeAlD
Pazopanib—MAP3K9—brain—multiple sclerosis	0.00119	0.00822	CbGeAlD
Pazopanib—FGF1—retina—multiple sclerosis	0.00118	0.00812	CbGeAlD
Pazopanib—TAOK1—nervous system—multiple sclerosis	0.00117	0.00807	CbGeAlD
Pazopanib—FGFR2—brainstem—multiple sclerosis	0.00115	0.00795	CbGeAlD
Pazopanib—TAOK1—central nervous system—multiple sclerosis	0.00113	0.00777	CbGeAlD
Pazopanib—RIOK2—midbrain—multiple sclerosis	0.00112	0.00774	CbGeAlD
Pazopanib—FGFR3—midbrain—multiple sclerosis	0.00112	0.00774	CbGeAlD
Pazopanib—STK36—medulla oblongata—multiple sclerosis	0.0011	0.0076	CbGeAlD
Pazopanib—SH2B3—nervous system—multiple sclerosis	0.0011	0.0076	CbGeAlD
Pazopanib—TAOK1—cerebellum—multiple sclerosis	0.0011	0.0076	CbGeAlD
Pazopanib—FGFR3—spinal cord—multiple sclerosis	0.0011	0.00755	CbGeAlD
Pazopanib—RIOK2—spinal cord—multiple sclerosis	0.0011	0.00755	CbGeAlD
Pazopanib—PI4KB—medulla oblongata—multiple sclerosis	0.00109	0.00749	CbGeAlD
Pazopanib—AURKC—nervous system—multiple sclerosis	0.00109	0.00748	CbGeAlD
Pazopanib—SH2B3—central nervous system—multiple sclerosis	0.00106	0.00732	CbGeAlD
Pazopanib—AURKC—central nervous system—multiple sclerosis	0.00104	0.0072	CbGeAlD
Pazopanib—SH2B3—cerebellum—multiple sclerosis	0.00104	0.00715	CbGeAlD
Pazopanib—FLT1—retina—multiple sclerosis	0.00103	0.00711	CbGeAlD
Pazopanib—TAOK3—brainstem—multiple sclerosis	0.00101	0.00695	CbGeAlD
Pazopanib—PI4KB—midbrain—multiple sclerosis	0.000993	0.00684	CbGeAlD
Pazopanib—TAOK3—retina—multiple sclerosis	0.000972	0.0067	CbGeAlD
Pazopanib—PI4KB—spinal cord—multiple sclerosis	0.000969	0.00668	CbGeAlD
Pazopanib—PIP4K2C—medulla oblongata—multiple sclerosis	0.000953	0.00657	CbGeAlD
Pazopanib—LIMK2—spinal cord—multiple sclerosis	0.000951	0.00656	CbGeAlD
Pazopanib—FGFR1—medulla oblongata—multiple sclerosis	0.000945	0.00652	CbGeAlD
Pazopanib—STK16—nervous system—multiple sclerosis	0.000937	0.00646	CbGeAlD
Pazopanib—LYN—nervous system—multiple sclerosis	0.000927	0.00639	CbGeAlD
Pazopanib—RIOK2—nervous system—multiple sclerosis	0.000923	0.00636	CbGeAlD
Pazopanib—FGFR3—nervous system—multiple sclerosis	0.000923	0.00636	CbGeAlD
Pazopanib—MAP3K19—nervous system—multiple sclerosis	0.000913	0.0063	CbGeAlD
Pazopanib—BMPR1B—nervous system—multiple sclerosis	0.000913	0.0063	CbGeAlD
Pazopanib—MAP2K5—brainstem—multiple sclerosis	0.000903	0.00623	CbGeAlD
Pazopanib—STK16—central nervous system—multiple sclerosis	0.000902	0.00622	CbGeAlD
Pazopanib—TAOK1—brain—multiple sclerosis	0.000895	0.00617	CbGeAlD
Pazopanib—LYN—central nervous system—multiple sclerosis	0.000893	0.00616	CbGeAlD
Pazopanib—FGFR3—central nervous system—multiple sclerosis	0.000888	0.00612	CbGeAlD
Pazopanib—RIOK2—central nervous system—multiple sclerosis	0.000888	0.00612	CbGeAlD
Pazopanib—STK16—cerebellum—multiple sclerosis	0.000882	0.00608	CbGeAlD
Pazopanib—MAP3K19—central nervous system—multiple sclerosis	0.000879	0.00606	CbGeAlD
Pazopanib—BMPR1B—central nervous system—multiple sclerosis	0.000879	0.00606	CbGeAlD
Pazopanib—KDR—retina—multiple sclerosis	0.000871	0.00601	CbGeAlD
Pazopanib—PIP4K2C—midbrain—multiple sclerosis	0.000871	0.00601	CbGeAlD
Pazopanib—RIOK2—cerebellum—multiple sclerosis	0.000868	0.00599	CbGeAlD
Pazopanib—FGFR3—cerebellum—multiple sclerosis	0.000868	0.00599	CbGeAlD
Pazopanib—FGFR1—midbrain—multiple sclerosis	0.000864	0.00596	CbGeAlD
Pazopanib—BMPR1B—cerebellum—multiple sclerosis	0.000859	0.00593	CbGeAlD
Pazopanib—FGF1—medulla oblongata—multiple sclerosis	0.000851	0.00587	CbGeAlD
Pazopanib—PIP4K2C—spinal cord—multiple sclerosis	0.00085	0.00586	CbGeAlD
Pazopanib—FGFR1—spinal cord—multiple sclerosis	0.000843	0.00581	CbGeAlD
Pazopanib—SH2B3—brain—multiple sclerosis	0.000843	0.00581	CbGeAlD
Pazopanib—AURKC—brain—multiple sclerosis	0.000829	0.00572	CbGeAlD
Pazopanib—STK36—nervous system—multiple sclerosis	0.000829	0.00571	CbGeAlD
Pazopanib—PI4KB—nervous system—multiple sclerosis	0.000816	0.00563	CbGeAlD
Pazopanib—LIMK2—nervous system—multiple sclerosis	0.000801	0.00552	CbGeAlD
Pazopanib—KIT—brainstem—multiple sclerosis	0.0008	0.00552	CbGeAlD
Pazopanib—STK36—central nervous system—multiple sclerosis	0.000798	0.0055	CbGeAlD
Pazopanib—PI4KB—central nervous system—multiple sclerosis	0.000786	0.00542	CbGeAlD
Pazopanib—STK36—cerebellum—multiple sclerosis	0.00078	0.00538	CbGeAlD
Pazopanib—FGF1—midbrain—multiple sclerosis	0.000778	0.00536	CbGeAlD
Pazopanib—LIMK2—central nervous system—multiple sclerosis	0.000771	0.00532	CbGeAlD
Pazopanib—PI4KB—cerebellum—multiple sclerosis	0.000768	0.00529	CbGeAlD
Pazopanib—FGF1—spinal cord—multiple sclerosis	0.000759	0.00523	CbGeAlD
Pazopanib—PLK4—brain—multiple sclerosis	0.000759	0.00523	CbGeAlD
Pazopanib—LIMK2—cerebellum—multiple sclerosis	0.000754	0.0052	CbGeAlD
Pazopanib—FLT1—medulla oblongata—multiple sclerosis	0.000745	0.00514	CbGeAlD
Pazopanib—EPHB6—medulla oblongata—multiple sclerosis	0.000736	0.00508	CbGeAlD
Pazopanib—FGFR2—spinal cord—multiple sclerosis	0.000717	0.00494	CbGeAlD
Pazopanib—STK16—brain—multiple sclerosis	0.000716	0.00494	CbGeAlD
Pazopanib—PIP4K2C—nervous system—multiple sclerosis	0.000716	0.00494	CbGeAlD
Pazopanib—LYN—brain—multiple sclerosis	0.000709	0.00489	CbGeAlD
Pazopanib—FGFR3—brain—multiple sclerosis	0.000705	0.00486	CbGeAlD
Pazopanib—RIOK2—brain—multiple sclerosis	0.000705	0.00486	CbGeAlD
Pazopanib—TAOK3—medulla oblongata—multiple sclerosis	0.000703	0.00484	CbGeAlD
Pazopanib—MAP3K19—brain—multiple sclerosis	0.000698	0.00481	CbGeAlD
Pazopanib—BMPR1B—brain—multiple sclerosis	0.000698	0.00481	CbGeAlD
Pazopanib—PIP4K2C—central nervous system—multiple sclerosis	0.000689	0.00475	CbGeAlD
Pazopanib—FLT1—midbrain—multiple sclerosis	0.000681	0.00469	CbGeAlD
Pazopanib—MAP3K2—nervous system—multiple sclerosis	0.000679	0.00468	CbGeAlD
Pazopanib—PIP4K2C—cerebellum—multiple sclerosis	0.000674	0.00465	CbGeAlD
Pazopanib—EPHB6—midbrain—multiple sclerosis	0.000673	0.00464	CbGeAlD
Pazopanib—FGFR1—cerebellum—multiple sclerosis	0.000668	0.00461	CbGeAlD
Pazopanib—FLT1—spinal cord—multiple sclerosis	0.000664	0.00458	CbGeAlD
Pazopanib—EPHB6—spinal cord—multiple sclerosis	0.000657	0.00453	CbGeAlD
Pazopanib—MAP3K2—central nervous system—multiple sclerosis	0.000654	0.00451	CbGeAlD
Pazopanib—TAOK3—midbrain—multiple sclerosis	0.000642	0.00443	CbGeAlD
Pazopanib—FGF1—nervous system—multiple sclerosis	0.00064	0.00441	CbGeAlD
Pazopanib—MAP3K2—cerebellum—multiple sclerosis	0.000639	0.0044	CbGeAlD
Pazopanib—STK36—brain—multiple sclerosis	0.000633	0.00437	CbGeAlD
Pazopanib—KDR—medulla oblongata—multiple sclerosis	0.00063	0.00434	CbGeAlD
Pazopanib—MAP2K5—medulla oblongata—multiple sclerosis	0.00063	0.00434	CbGeAlD
Pazopanib—TAOK3—spinal cord—multiple sclerosis	0.000627	0.00432	CbGeAlD
Pazopanib—PI4KB—brain—multiple sclerosis	0.000624	0.0043	CbGeAlD
Pazopanib—PDGFRA—spinal cord—multiple sclerosis	0.000623	0.00429	CbGeAlD
Pazopanib—FGF1—central nervous system—multiple sclerosis	0.000616	0.00424	CbGeAlD
Pazopanib—CSF1R—medulla oblongata—multiple sclerosis	0.000615	0.00424	CbGeAlD
Pazopanib—LIMK2—brain—multiple sclerosis	0.000612	0.00422	CbGeAlD
Pazopanib—FGFR2—nervous system—multiple sclerosis	0.000604	0.00416	CbGeAlD
Pazopanib—FGF1—cerebellum—multiple sclerosis	0.000602	0.00415	CbGeAlD
Pazopanib—FGFR2—central nervous system—multiple sclerosis	0.000581	0.00401	CbGeAlD
Pazopanib—KDR—midbrain—multiple sclerosis	0.000576	0.00397	CbGeAlD
Pazopanib—MAP2K5—midbrain—multiple sclerosis	0.000576	0.00397	CbGeAlD
Pazopanib—FGFR2—cerebellum—multiple sclerosis	0.000568	0.00392	CbGeAlD
Pazopanib—CSF1R—midbrain—multiple sclerosis	0.000562	0.00387	CbGeAlD
Pazopanib—KDR—spinal cord—multiple sclerosis	0.000562	0.00387	CbGeAlD
Pazopanib—MAP2K5—spinal cord—multiple sclerosis	0.000562	0.00387	CbGeAlD
Pazopanib—FLT1—nervous system—multiple sclerosis	0.00056	0.00386	CbGeAlD
Pazopanib—KIT—medulla oblongata—multiple sclerosis	0.000558	0.00385	CbGeAlD
Pazopanib—EPHB6—nervous system—multiple sclerosis	0.000553	0.00382	CbGeAlD
Pazopanib—FLT4—brain—multiple sclerosis	0.00055	0.00379	CbGeAlD
Pazopanib—CSF1R—spinal cord—multiple sclerosis	0.000548	0.00378	CbGeAlD
Pazopanib—PIP4K2C—brain—multiple sclerosis	0.000547	0.00377	CbGeAlD
Pazopanib—PDGFRB—medulla oblongata—multiple sclerosis	0.000545	0.00376	CbGeAlD
Pazopanib—FGFR1—brain—multiple sclerosis	0.000543	0.00374	CbGeAlD
Pazopanib—FLT1—central nervous system—multiple sclerosis	0.000539	0.00372	CbGeAlD
Pazopanib—EPHB6—central nervous system—multiple sclerosis	0.000533	0.00367	CbGeAlD
Pazopanib—STK10—nervous system—multiple sclerosis	0.00053	0.00365	CbGeAlD
Pazopanib—TAOK3—nervous system—multiple sclerosis	0.000528	0.00364	CbGeAlD
Pazopanib—FLT1—cerebellum—multiple sclerosis	0.000527	0.00363	CbGeAlD
Pazopanib—PDGFRA—nervous system—multiple sclerosis	0.000525	0.00362	CbGeAlD
Pazopanib—EPHB6—cerebellum—multiple sclerosis	0.000521	0.00359	CbGeAlD
Pazopanib—MAP3K2—brain—multiple sclerosis	0.000519	0.00358	CbGeAlD
Pazopanib—STK10—central nervous system—multiple sclerosis	0.00051	0.00352	CbGeAlD
Pazopanib—KIT—midbrain—multiple sclerosis	0.00051	0.00352	CbGeAlD
Pazopanib—TAOK3—central nervous system—multiple sclerosis	0.000508	0.0035	CbGeAlD
Pazopanib—PDGFRA—central nervous system—multiple sclerosis	0.000505	0.00348	CbGeAlD
Pazopanib—STK10—cerebellum—multiple sclerosis	0.000499	0.00344	CbGeAlD
Pazopanib—PDGFRB—midbrain—multiple sclerosis	0.000498	0.00343	CbGeAlD
Pazopanib—KIT—spinal cord—multiple sclerosis	0.000498	0.00343	CbGeAlD
Pazopanib—TAOK3—cerebellum—multiple sclerosis	0.000497	0.00342	CbGeAlD
Pazopanib—PDGFRA—cerebellum—multiple sclerosis	0.000494	0.0034	CbGeAlD
Pazopanib—FGF1—brain—multiple sclerosis	0.000489	0.00337	CbGeAlD
Pazopanib—SH2B3—Betamethasone—Methylprednisolone—multiple sclerosis	0.000489	0.105	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000489	0.105	CbGdCrCtD
Pazopanib—PDGFRB—spinal cord—multiple sclerosis	0.000486	0.00335	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Betamethasone—multiple sclerosis	0.000481	0.104	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Dexamethasone—multiple sclerosis	0.000481	0.104	CbGdCrCtD
Pazopanib—KDR—nervous system—multiple sclerosis	0.000473	0.00326	CbGeAlD
Pazopanib—MAP2K5—nervous system—multiple sclerosis	0.000473	0.00326	CbGeAlD
Pazopanib—SH2B3—Betamethasone—Triamcinolone—multiple sclerosis	0.00047	0.101	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Triamcinolone—multiple sclerosis	0.00047	0.101	CbGdCrCtD
Pazopanib—CSF1R—nervous system—multiple sclerosis	0.000462	0.00318	CbGeAlD
Pazopanib—FGFR2—brain—multiple sclerosis	0.000462	0.00318	CbGeAlD
Pazopanib—KDR—central nervous system—multiple sclerosis	0.000456	0.00314	CbGeAlD
Pazopanib—MAP2K5—central nervous system—multiple sclerosis	0.000456	0.00314	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Prednisone—multiple sclerosis	0.000446	0.0961	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisone—multiple sclerosis	0.000446	0.0961	CbGdCrCtD
Pazopanib—KDR—cerebellum—multiple sclerosis	0.000445	0.00307	CbGeAlD
Pazopanib—MAP2K5—cerebellum—multiple sclerosis	0.000445	0.00307	CbGeAlD
Pazopanib—CSF1R—central nervous system—multiple sclerosis	0.000445	0.00307	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Prednisolone—multiple sclerosis	0.000435	0.0938	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisolone—multiple sclerosis	0.000435	0.0938	CbGdCrCtD
Pazopanib—CSF1R—cerebellum—multiple sclerosis	0.000435	0.003	CbGeAlD
Pazopanib—FLT1—brain—multiple sclerosis	0.000428	0.00295	CbGeAlD
Pazopanib—EPHB6—brain—multiple sclerosis	0.000423	0.00292	CbGeAlD
Pazopanib—KIT—nervous system—multiple sclerosis	0.000419	0.00289	CbGeAlD
Pazopanib—PDGFRB—nervous system—multiple sclerosis	0.00041	0.00282	CbGeAlD
Pazopanib—STK10—brain—multiple sclerosis	0.000405	0.00279	CbGeAlD
Pazopanib—KIT—central nervous system—multiple sclerosis	0.000404	0.00278	CbGeAlD
Pazopanib—TAOK3—brain—multiple sclerosis	0.000404	0.00278	CbGeAlD
Pazopanib—PDGFRA—brain—multiple sclerosis	0.000401	0.00276	CbGeAlD
Pazopanib—KIT—cerebellum—multiple sclerosis	0.000395	0.00272	CbGeAlD
Pazopanib—PDGFRB—central nervous system—multiple sclerosis	0.000394	0.00272	CbGeAlD
Pazopanib—PDGFRB—cerebellum—multiple sclerosis	0.000385	0.00266	CbGeAlD
Pazopanib—KDR—brain—multiple sclerosis	0.000362	0.00249	CbGeAlD
Pazopanib—MAP2K5—brain—multiple sclerosis	0.000362	0.00249	CbGeAlD
Pazopanib—CSF1R—brain—multiple sclerosis	0.000353	0.00243	CbGeAlD
Pazopanib—KIT—brain—multiple sclerosis	0.000321	0.00221	CbGeAlD
Pazopanib—PDGFRB—brain—multiple sclerosis	0.000313	0.00216	CbGeAlD
Pazopanib—ABCG2—medulla oblongata—multiple sclerosis	0.000306	0.00211	CbGeAlD
Pazopanib—CYP2D6—brainstem—multiple sclerosis	0.000301	0.00208	CbGeAlD
Pazopanib—ABCG2—midbrain—multiple sclerosis	0.00028	0.00193	CbGeAlD
Pazopanib—ABCG2—spinal cord—multiple sclerosis	0.000273	0.00188	CbGeAlD
Pazopanib—ABCG2—cerebellum—multiple sclerosis	0.000217	0.00149	CbGeAlD
Pazopanib—ABCB1—retina—multiple sclerosis	0.000209	0.00144	CbGeAlD
Pazopanib—CYP2C8—brain—multiple sclerosis	0.000181	0.00125	CbGeAlD
Pazopanib—ABCG2—brain—multiple sclerosis	0.000176	0.00121	CbGeAlD
Pazopanib—Angiopathy—Dexamethasone—multiple sclerosis	0.000169	0.00078	CcSEcCtD
Pazopanib—Angiopathy—Betamethasone—multiple sclerosis	0.000169	0.00078	CcSEcCtD
Pazopanib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000168	0.000776	CcSEcCtD
Pazopanib—Hypertension—Prednisolone—multiple sclerosis	0.000168	0.000775	CcSEcCtD
Pazopanib—Fatigue—Mitoxantrone—multiple sclerosis	0.000167	0.00077	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—multiple sclerosis	0.000167	0.000767	CcSEcCtD
Pazopanib—Pain—Mitoxantrone—multiple sclerosis	0.000166	0.000763	CcSEcCtD
Pazopanib—Bradycardia—Prednisone—multiple sclerosis	0.000166	0.000763	CcSEcCtD
Pazopanib—Alopecia—Dexamethasone—multiple sclerosis	0.000165	0.00076	CcSEcCtD
Pazopanib—Alopecia—Betamethasone—multiple sclerosis	0.000165	0.00076	CcSEcCtD
Pazopanib—Diarrhoea—Azathioprine—multiple sclerosis	0.000164	0.000756	CcSEcCtD
Pazopanib—Haemoglobin—Prednisone—multiple sclerosis	0.000163	0.000753	CcSEcCtD
Pazopanib—Haemorrhage—Prednisone—multiple sclerosis	0.000163	0.000749	CcSEcCtD
Pazopanib—Erythema—Betamethasone—multiple sclerosis	0.000163	0.000749	CcSEcCtD
Pazopanib—Erythema—Dexamethasone—multiple sclerosis	0.000163	0.000749	CcSEcCtD
Pazopanib—Syncope—Triamcinolone—multiple sclerosis	0.000161	0.00074	CcSEcCtD
Pazopanib—CYP3A4—nervous system—multiple sclerosis	0.00016	0.00111	CbGeAlD
Pazopanib—Syncope—Methylprednisolone—multiple sclerosis	0.00016	0.000738	CcSEcCtD
Pazopanib—Connective tissue disorder—Prednisone—multiple sclerosis	0.00016	0.000736	CcSEcCtD
Pazopanib—Oedema—Prednisolone—multiple sclerosis	0.000159	0.000732	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—multiple sclerosis	0.000159	0.000731	CcSEcCtD
Pazopanib—Dizziness—Azathioprine—multiple sclerosis	0.000159	0.00073	CcSEcCtD
Pazopanib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000158	0.00073	CcSEcCtD
Pazopanib—CYP2D6—nervous system—multiple sclerosis	0.000158	0.00109	CbGeAlD
Pazopanib—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000157	0.000725	CcSEcCtD
Pazopanib—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000157	0.000724	CcSEcCtD
Pazopanib—Shock—Prednisolone—multiple sclerosis	0.000156	0.00072	CcSEcCtD
Pazopanib—Cough—Triamcinolone—multiple sclerosis	0.000156	0.00072	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000155	0.000714	CcSEcCtD
Pazopanib—Hypertension—Triamcinolone—multiple sclerosis	0.000155	0.000712	CcSEcCtD
Pazopanib—CYP3A4—central nervous system—multiple sclerosis	0.000154	0.00106	CbGeAlD
Pazopanib—Hypertension—Methylprednisolone—multiple sclerosis	0.000154	0.000711	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000154	0.000708	CcSEcCtD
Pazopanib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000153	0.000706	CcSEcCtD
Pazopanib—Myalgia—Triamcinolone—multiple sclerosis	0.000153	0.000703	CcSEcCtD
Pazopanib—Vomiting—Azathioprine—multiple sclerosis	0.000152	0.000702	CcSEcCtD
Pazopanib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000152	0.000701	CcSEcCtD
Pazopanib—Myalgia—Methylprednisolone—multiple sclerosis	0.000152	0.000701	CcSEcCtD
Pazopanib—Eye disorder—Prednisone—multiple sclerosis	0.000152	0.0007	CcSEcCtD
Pazopanib—CYP2D6—central nervous system—multiple sclerosis	0.000152	0.00105	CbGeAlD
Pazopanib—Infestation—Methotrexate—multiple sclerosis	0.000151	0.000697	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—multiple sclerosis	0.000151	0.000697	CcSEcCtD
Pazopanib—Rash—Azathioprine—multiple sclerosis	0.000151	0.000696	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000151	0.000696	CcSEcCtD
Pazopanib—ABCB1—medulla oblongata—multiple sclerosis	0.000151	0.00104	CbGeAlD
Pazopanib—Dermatitis—Azathioprine—multiple sclerosis	0.000151	0.000696	CcSEcCtD
Pazopanib—Flushing—Prednisone—multiple sclerosis	0.000151	0.000695	CcSEcCtD
Pazopanib—Headache—Azathioprine—multiple sclerosis	0.00015	0.000692	CcSEcCtD
Pazopanib—Dry mouth—Triamcinolone—multiple sclerosis	0.000149	0.000687	CcSEcCtD
Pazopanib—CYP2D6—cerebellum—multiple sclerosis	0.000149	0.00102	CbGeAlD
Pazopanib—Stomatitis—Methotrexate—multiple sclerosis	0.000148	0.00068	CcSEcCtD
Pazopanib—Angiopathy—Prednisone—multiple sclerosis	0.000148	0.00068	CcSEcCtD
Pazopanib—Oedema—Triamcinolone—multiple sclerosis	0.000146	0.000673	CcSEcCtD
Pazopanib—Syncope—Dexamethasone—multiple sclerosis	0.000146	0.000671	CcSEcCtD
Pazopanib—Syncope—Betamethasone—multiple sclerosis	0.000146	0.000671	CcSEcCtD
Pazopanib—Infection—Triamcinolone—multiple sclerosis	0.000145	0.000669	CcSEcCtD
Pazopanib—Infection—Methylprednisolone—multiple sclerosis	0.000145	0.000668	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—multiple sclerosis	0.000144	0.000665	CcSEcCtD
Pazopanib—Shock—Triamcinolone—multiple sclerosis	0.000144	0.000663	CcSEcCtD
Pazopanib—Insomnia—Prednisolone—multiple sclerosis	0.000144	0.000662	CcSEcCtD
Pazopanib—Alopecia—Prednisone—multiple sclerosis	0.000144	0.000662	CcSEcCtD
Pazopanib—Shock—Methylprednisolone—multiple sclerosis	0.000144	0.000661	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000143	0.000659	CcSEcCtD
Pazopanib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000143	0.000659	CcSEcCtD
Pazopanib—Loss of consciousness—Betamethasone—multiple sclerosis	0.000143	0.000658	CcSEcCtD
Pazopanib—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000143	0.000658	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—multiple sclerosis	0.000143	0.000658	CcSEcCtD
Pazopanib—Paraesthesia—Prednisolone—multiple sclerosis	0.000143	0.000658	CcSEcCtD
Pazopanib—Mental disorder—Prednisone—multiple sclerosis	0.000142	0.000656	CcSEcCtD
Pazopanib—Nausea—Azathioprine—multiple sclerosis	0.000142	0.000656	CcSEcCtD
Pazopanib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000142	0.000653	CcSEcCtD
Pazopanib—Erythema—Prednisone—multiple sclerosis	0.000142	0.000652	CcSEcCtD
Pazopanib—Malnutrition—Prednisone—multiple sclerosis	0.000142	0.000652	CcSEcCtD
Pazopanib—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000141	0.000651	CcSEcCtD
Pazopanib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000141	0.00065	CcSEcCtD
Pazopanib—Hypertension—Dexamethasone—multiple sclerosis	0.00014	0.000646	CcSEcCtD
Pazopanib—Hypertension—Betamethasone—multiple sclerosis	0.00014	0.000646	CcSEcCtD
Pazopanib—Asthenia—Mitoxantrone—multiple sclerosis	0.000139	0.00064	CcSEcCtD
Pazopanib—Myalgia—Betamethasone—multiple sclerosis	0.000138	0.000637	CcSEcCtD
Pazopanib—Myalgia—Dexamethasone—multiple sclerosis	0.000138	0.000637	CcSEcCtD
Pazopanib—ABCB1—midbrain—multiple sclerosis	0.000138	0.000952	CbGeAlD
Pazopanib—Haemoglobin—Methotrexate—multiple sclerosis	0.000137	0.000629	CcSEcCtD
Pazopanib—Pain—Prednisolone—multiple sclerosis	0.000136	0.000626	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—multiple sclerosis	0.000136	0.000626	CcSEcCtD
Pazopanib—ABCB1—spinal cord—multiple sclerosis	0.000135	0.000929	CbGeAlD
Pazopanib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000134	0.000618	CcSEcCtD
Pazopanib—Vision blurred—Prednisone—multiple sclerosis	0.000133	0.000615	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—multiple sclerosis	0.000133	0.000614	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000133	0.000614	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000133	0.000612	CcSEcCtD
Pazopanib—Oedema—Dexamethasone—multiple sclerosis	0.000133	0.000611	CcSEcCtD
Pazopanib—Oedema—Betamethasone—multiple sclerosis	0.000133	0.000611	CcSEcCtD
Pazopanib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000133	0.000611	CcSEcCtD
Pazopanib—Insomnia—Triamcinolone—multiple sclerosis	0.000132	0.000609	CcSEcCtD
Pazopanib—Insomnia—Methylprednisolone—multiple sclerosis	0.000132	0.000608	CcSEcCtD
Pazopanib—Infection—Betamethasone—multiple sclerosis	0.000132	0.000607	CcSEcCtD
Pazopanib—Infection—Dexamethasone—multiple sclerosis	0.000132	0.000607	CcSEcCtD
Pazopanib—Paraesthesia—Triamcinolone—multiple sclerosis	0.000131	0.000605	CcSEcCtD
Pazopanib—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000131	0.000603	CcSEcCtD
Pazopanib—Anaemia—Prednisone—multiple sclerosis	0.000131	0.000603	CcSEcCtD
Pazopanib—Shock—Dexamethasone—multiple sclerosis	0.000131	0.000601	CcSEcCtD
Pazopanib—Shock—Betamethasone—multiple sclerosis	0.000131	0.000601	CcSEcCtD
Pazopanib—Dyspnoea—Triamcinolone—multiple sclerosis	0.00013	0.0006	CcSEcCtD
Pazopanib—Nervous system disorder—Betamethasone—multiple sclerosis	0.00013	0.000599	CcSEcCtD
Pazopanib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00013	0.000599	CcSEcCtD
Pazopanib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.00013	0.000598	CcSEcCtD
Pazopanib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.00013	0.000598	CcSEcCtD
Pazopanib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000129	0.000593	CcSEcCtD
Pazopanib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000128	0.000591	CcSEcCtD
Pazopanib—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000128	0.000591	CcSEcCtD
Pazopanib—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000128	0.000591	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—multiple sclerosis	0.000127	0.000585	CcSEcCtD
Pazopanib—Syncope—Prednisone—multiple sclerosis	0.000127	0.000585	CcSEcCtD
Pazopanib—Anorexia—Betamethasone—multiple sclerosis	0.000126	0.000582	CcSEcCtD
Pazopanib—Anorexia—Dexamethasone—multiple sclerosis	0.000126	0.000582	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000126	0.000581	CcSEcCtD
Pazopanib—Fatigue—Triamcinolone—multiple sclerosis	0.000126	0.000581	CcSEcCtD
Pazopanib—Fatigue—Methylprednisolone—multiple sclerosis	0.000126	0.000579	CcSEcCtD
Pazopanib—Pain—Triamcinolone—multiple sclerosis	0.000125	0.000576	CcSEcCtD
Pazopanib—Loss of consciousness—Prednisone—multiple sclerosis	0.000124	0.000573	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—multiple sclerosis	0.000123	0.000568	CcSEcCtD
Pazopanib—Vomiting—Mitoxantrone—multiple sclerosis	0.000123	0.000568	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000123	0.000564	CcSEcCtD
Pazopanib—Hypertension—Prednisone—multiple sclerosis	0.000122	0.000563	CcSEcCtD
Pazopanib—Rash—Mitoxantrone—multiple sclerosis	0.000122	0.000563	CcSEcCtD
Pazopanib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000122	0.000562	CcSEcCtD
Pazopanib—Chills—Methotrexate—multiple sclerosis	0.000122	0.000562	CcSEcCtD
Pazopanib—Headache—Mitoxantrone—multiple sclerosis	0.000121	0.000559	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000121	0.000557	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000121	0.000557	CcSEcCtD
Pazopanib—CYP2D6—brain—multiple sclerosis	0.000121	0.000832	CbGeAlD
Pazopanib—Arthralgia—Prednisone—multiple sclerosis	0.000121	0.000555	CcSEcCtD
Pazopanib—Myalgia—Prednisone—multiple sclerosis	0.000121	0.000555	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—multiple sclerosis	0.00012	0.000553	CcSEcCtD
Pazopanib—Insomnia—Betamethasone—multiple sclerosis	0.00012	0.000553	CcSEcCtD
Pazopanib—Insomnia—Dexamethasone—multiple sclerosis	0.00012	0.000553	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00012	0.000551	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000119	0.000549	CcSEcCtD
Pazopanib—Paraesthesia—Betamethasone—multiple sclerosis	0.000119	0.000549	CcSEcCtD
Pazopanib—Paraesthesia—Dexamethasone—multiple sclerosis	0.000119	0.000549	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—multiple sclerosis	0.000119	0.000548	CcSEcCtD
Pazopanib—Erythema—Methotrexate—multiple sclerosis	0.000118	0.000545	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—multiple sclerosis	0.000118	0.000545	CcSEcCtD
Pazopanib—Dyspepsia—Dexamethasone—multiple sclerosis	0.000117	0.000538	CcSEcCtD
Pazopanib—Dyspepsia—Betamethasone—multiple sclerosis	0.000117	0.000538	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—multiple sclerosis	0.000116	0.000534	CcSEcCtD
Pazopanib—Oedema—Prednisone—multiple sclerosis	0.000116	0.000532	CcSEcCtD
Pazopanib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000115	0.000531	CcSEcCtD
Pazopanib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000115	0.000531	CcSEcCtD
Pazopanib—Decreased appetite—Betamethasone—multiple sclerosis	0.000115	0.000531	CcSEcCtD
Pazopanib—Nausea—Mitoxantrone—multiple sclerosis	0.000115	0.00053	CcSEcCtD
Pazopanib—Infection—Prednisone—multiple sclerosis	0.000115	0.000529	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000115	0.000528	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000115	0.000528	CcSEcCtD
Pazopanib—Fatigue—Betamethasone—multiple sclerosis	0.000114	0.000527	CcSEcCtD
Pazopanib—Fatigue—Dexamethasone—multiple sclerosis	0.000114	0.000527	CcSEcCtD
Pazopanib—Shock—Prednisone—multiple sclerosis	0.000114	0.000524	CcSEcCtD
Pazopanib—ABCB1—nervous system—multiple sclerosis	0.000114	0.000783	CbGeAlD
Pazopanib—Pain—Betamethasone—multiple sclerosis	0.000113	0.000523	CcSEcCtD
Pazopanib—Pain—Dexamethasone—multiple sclerosis	0.000113	0.000523	CcSEcCtD
Pazopanib—Nervous system disorder—Prednisone—multiple sclerosis	0.000113	0.000522	CcSEcCtD
Pazopanib—Skin disorder—Prednisone—multiple sclerosis	0.000112	0.000517	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisone—multiple sclerosis	0.000112	0.000514	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—multiple sclerosis	0.000112	0.000514	CcSEcCtD
Pazopanib—Anorexia—Prednisone—multiple sclerosis	0.00011	0.000507	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—multiple sclerosis	0.000109	0.000504	CcSEcCtD
Pazopanib—ABCB1—central nervous system—multiple sclerosis	0.000109	0.000754	CbGeAlD
Pazopanib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000109	0.0005	CcSEcCtD
Pazopanib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000109	0.0005	CcSEcCtD
Pazopanib—ABCB1—cerebellum—multiple sclerosis	0.000107	0.000737	CbGeAlD
Pazopanib—Leukopenia—Methotrexate—multiple sclerosis	0.000106	0.000488	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000105	0.000485	CcSEcCtD
Pazopanib—Dizziness—Prednisolone—multiple sclerosis	0.000105	0.000484	CcSEcCtD
Pazopanib—Asthenia—Triamcinolone—multiple sclerosis	0.000105	0.000483	CcSEcCtD
Pazopanib—Abdominal pain—Betamethasone—multiple sclerosis	0.000105	0.000483	CcSEcCtD
Pazopanib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000105	0.000483	CcSEcCtD
Pazopanib—Asthenia—Methylprednisolone—multiple sclerosis	0.000105	0.000482	CcSEcCtD
Pazopanib—Insomnia—Prednisone—multiple sclerosis	0.000105	0.000481	CcSEcCtD
Pazopanib—Paraesthesia—Prednisone—multiple sclerosis	0.000104	0.000478	CcSEcCtD
Pazopanib—Pruritus—Triamcinolone—multiple sclerosis	0.000103	0.000476	CcSEcCtD
Pazopanib—Cough—Methotrexate—multiple sclerosis	0.000103	0.000476	CcSEcCtD
Pazopanib—Pruritus—Methylprednisolone—multiple sclerosis	0.000103	0.000475	CcSEcCtD
Pazopanib—Dyspepsia—Prednisone—multiple sclerosis	0.000102	0.000468	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—multiple sclerosis	0.000101	0.000464	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—multiple sclerosis	0.000101	0.000464	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—multiple sclerosis	0.000101	0.000464	CcSEcCtD
Pazopanib—Decreased appetite—Prednisone—multiple sclerosis	0.0001	0.000463	CcSEcCtD
Pazopanib—Rash—Prednisolone—multiple sclerosis	0.0001	0.000462	CcSEcCtD
Pazopanib—Dermatitis—Prednisolone—multiple sclerosis	0.0001	0.000461	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.0001	0.000461	CcSEcCtD
Pazopanib—Diarrhoea—Methylprednisolone—multiple sclerosis	9.98e-05	0.00046	CcSEcCtD
Pazopanib—Fatigue—Prednisone—multiple sclerosis	9.96e-05	0.000459	CcSEcCtD
Pazopanib—Headache—Prednisolone—multiple sclerosis	9.96e-05	0.000459	CcSEcCtD
Pazopanib—Dizziness—Triamcinolone—multiple sclerosis	9.67e-05	0.000445	CcSEcCtD
Pazopanib—Dizziness—Methylprednisolone—multiple sclerosis	9.65e-05	0.000444	CcSEcCtD
Pazopanib—Infection—Methotrexate—multiple sclerosis	9.59e-05	0.000442	CcSEcCtD
Pazopanib—Asthenia—Betamethasone—multiple sclerosis	9.52e-05	0.000438	CcSEcCtD
Pazopanib—Asthenia—Dexamethasone—multiple sclerosis	9.52e-05	0.000438	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—multiple sclerosis	9.47e-05	0.000436	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—multiple sclerosis	9.46e-05	0.000435	CcSEcCtD
Pazopanib—Gastrointestinal pain—Prednisone—multiple sclerosis	9.45e-05	0.000435	CcSEcCtD
Pazopanib—Nausea—Prednisolone—multiple sclerosis	9.45e-05	0.000435	CcSEcCtD
Pazopanib—Pruritus—Dexamethasone—multiple sclerosis	9.39e-05	0.000432	CcSEcCtD
Pazopanib—Pruritus—Betamethasone—multiple sclerosis	9.39e-05	0.000432	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—multiple sclerosis	9.38e-05	0.000432	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—multiple sclerosis	9.34e-05	0.00043	CcSEcCtD
Pazopanib—Vomiting—Triamcinolone—multiple sclerosis	9.3e-05	0.000428	CcSEcCtD
Pazopanib—Vomiting—Methylprednisolone—multiple sclerosis	9.28e-05	0.000427	CcSEcCtD
Pazopanib—Rash—Triamcinolone—multiple sclerosis	9.22e-05	0.000425	CcSEcCtD
Pazopanib—Dermatitis—Triamcinolone—multiple sclerosis	9.21e-05	0.000424	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—multiple sclerosis	9.21e-05	0.000424	CcSEcCtD
Pazopanib—Rash—Methylprednisolone—multiple sclerosis	9.2e-05	0.000424	CcSEcCtD
Pazopanib—Dermatitis—Methylprednisolone—multiple sclerosis	9.19e-05	0.000423	CcSEcCtD
Pazopanib—Headache—Triamcinolone—multiple sclerosis	9.16e-05	0.000422	CcSEcCtD
Pazopanib—Headache—Methylprednisolone—multiple sclerosis	9.14e-05	0.000421	CcSEcCtD
Pazopanib—Abdominal pain—Prednisone—multiple sclerosis	9.13e-05	0.000421	CcSEcCtD
Pazopanib—Diarrhoea—Betamethasone—multiple sclerosis	9.08e-05	0.000418	CcSEcCtD
Pazopanib—Diarrhoea—Dexamethasone—multiple sclerosis	9.08e-05	0.000418	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	8.8e-05	0.000405	CcSEcCtD
Pazopanib—Dizziness—Betamethasone—multiple sclerosis	8.77e-05	0.000404	CcSEcCtD
Pazopanib—Dizziness—Dexamethasone—multiple sclerosis	8.77e-05	0.000404	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—multiple sclerosis	8.73e-05	0.000402	CcSEcCtD
Pazopanib—Nausea—Triamcinolone—multiple sclerosis	8.69e-05	0.0004	CcSEcCtD
Pazopanib—ABCB1—brain—multiple sclerosis	8.68e-05	0.000598	CbGeAlD
Pazopanib—Paraesthesia—Methotrexate—multiple sclerosis	8.67e-05	0.000399	CcSEcCtD
Pazopanib—Nausea—Methylprednisolone—multiple sclerosis	8.67e-05	0.000399	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—multiple sclerosis	8.61e-05	0.000397	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—multiple sclerosis	8.59e-05	0.000395	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—multiple sclerosis	8.5e-05	0.000391	CcSEcCtD
Pazopanib—Vomiting—Dexamethasone—multiple sclerosis	8.44e-05	0.000389	CcSEcCtD
Pazopanib—Vomiting—Betamethasone—multiple sclerosis	8.44e-05	0.000389	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—multiple sclerosis	8.4e-05	0.000387	CcSEcCtD
Pazopanib—Rash—Betamethasone—multiple sclerosis	8.37e-05	0.000385	CcSEcCtD
Pazopanib—Rash—Dexamethasone—multiple sclerosis	8.37e-05	0.000385	CcSEcCtD
Pazopanib—Dermatitis—Dexamethasone—multiple sclerosis	8.36e-05	0.000385	CcSEcCtD
Pazopanib—Dermatitis—Betamethasone—multiple sclerosis	8.36e-05	0.000385	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	8.34e-05	0.000384	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—multiple sclerosis	8.33e-05	0.000383	CcSEcCtD
Pazopanib—Headache—Betamethasone—multiple sclerosis	8.31e-05	0.000383	CcSEcCtD
Pazopanib—Headache—Dexamethasone—multiple sclerosis	8.31e-05	0.000383	CcSEcCtD
Pazopanib—Asthenia—Prednisone—multiple sclerosis	8.29e-05	0.000382	CcSEcCtD
Pazopanib—Pain—Methotrexate—multiple sclerosis	8.26e-05	0.00038	CcSEcCtD
Pazopanib—Pruritus—Prednisone—multiple sclerosis	8.18e-05	0.000377	CcSEcCtD
Pazopanib—Diarrhoea—Prednisone—multiple sclerosis	7.91e-05	0.000364	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.9e-05	0.000364	CcSEcCtD
Pazopanib—Nausea—Betamethasone—multiple sclerosis	7.88e-05	0.000363	CcSEcCtD
Pazopanib—Nausea—Dexamethasone—multiple sclerosis	7.88e-05	0.000363	CcSEcCtD
Pazopanib—Dizziness—Prednisone—multiple sclerosis	7.64e-05	0.000352	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—multiple sclerosis	7.63e-05	0.000352	CcSEcCtD
Pazopanib—Vomiting—Prednisone—multiple sclerosis	7.35e-05	0.000338	CcSEcCtD
Pazopanib—Rash—Prednisone—multiple sclerosis	7.29e-05	0.000336	CcSEcCtD
Pazopanib—Dermatitis—Prednisone—multiple sclerosis	7.28e-05	0.000335	CcSEcCtD
Pazopanib—Headache—Prednisone—multiple sclerosis	7.24e-05	0.000333	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—multiple sclerosis	6.93e-05	0.000319	CcSEcCtD
Pazopanib—Nausea—Prednisone—multiple sclerosis	6.86e-05	0.000316	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—multiple sclerosis	6.83e-05	0.000315	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—multiple sclerosis	6.61e-05	0.000304	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—multiple sclerosis	6.39e-05	0.000294	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—multiple sclerosis	6.14e-05	0.000283	CcSEcCtD
Pazopanib—Rash—Methotrexate—multiple sclerosis	6.09e-05	0.00028	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—multiple sclerosis	6.08e-05	0.00028	CcSEcCtD
Pazopanib—Headache—Methotrexate—multiple sclerosis	6.05e-05	0.000279	CcSEcCtD
Pazopanib—Nausea—Methotrexate—multiple sclerosis	5.74e-05	0.000264	CcSEcCtD
Pazopanib—FGFR1—Signaling Pathways—APOE—multiple sclerosis	6.54e-06	2.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—APOE—multiple sclerosis	6.53e-06	2.59e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SPP1—multiple sclerosis	6.51e-06	2.58e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IFNG—multiple sclerosis	6.5e-06	2.58e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MAPK1—multiple sclerosis	6.49e-06	2.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—IL6—multiple sclerosis	6.49e-06	2.58e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL2—multiple sclerosis	6.48e-06	2.57e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TYK2—multiple sclerosis	6.48e-06	2.57e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—STAT3—multiple sclerosis	6.48e-06	2.57e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—IL6—multiple sclerosis	6.47e-06	2.57e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCR5—multiple sclerosis	6.46e-06	2.57e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—IL6—multiple sclerosis	6.46e-06	2.57e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL1B—multiple sclerosis	6.45e-06	2.56e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CD4—multiple sclerosis	6.45e-06	2.56e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—APOE—multiple sclerosis	6.44e-06	2.56e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL1B—multiple sclerosis	6.44e-06	2.56e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CD4—multiple sclerosis	6.43e-06	2.56e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL2—multiple sclerosis	6.43e-06	2.55e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL2—multiple sclerosis	6.41e-06	2.55e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TYK2—multiple sclerosis	6.41e-06	2.55e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—MAPK1—multiple sclerosis	6.38e-06	2.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2RA—multiple sclerosis	6.37e-06	2.53e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IFNG—multiple sclerosis	6.36e-06	2.53e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GPC5—multiple sclerosis	6.36e-06	2.53e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CD80—multiple sclerosis	6.35e-06	2.52e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCR5—multiple sclerosis	6.33e-06	2.51e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD4—multiple sclerosis	6.28e-06	2.49e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2RA—multiple sclerosis	6.24e-06	2.48e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CD80—multiple sclerosis	6.23e-06	2.48e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD4—multiple sclerosis	6.15e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MMP9—multiple sclerosis	6.14e-06	2.44e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CD80—multiple sclerosis	6.09e-06	2.42e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—MAPK1—multiple sclerosis	6.09e-06	2.42e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—POMC—multiple sclerosis	6.03e-06	2.4e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MYC—multiple sclerosis	6.02e-06	2.39e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—TGFB1—multiple sclerosis	6e-06	2.38e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.97e-06	2.37e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—POMC—multiple sclerosis	5.92e-06	2.35e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CD80—multiple sclerosis	5.92e-06	2.35e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—APOE—multiple sclerosis	5.91e-06	2.34e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CD80—multiple sclerosis	5.9e-06	2.34e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCL2—multiple sclerosis	5.9e-06	2.34e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL6—multiple sclerosis	5.89e-06	2.34e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MAPK1—multiple sclerosis	5.89e-06	2.34e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—APOE—multiple sclerosis	5.88e-06	2.34e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CD86—multiple sclerosis	5.85e-06	2.32e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—IL6—multiple sclerosis	5.83e-06	2.31e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—STAT3—multiple sclerosis	5.8e-06	2.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1B—multiple sclerosis	5.8e-06	2.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CD4—multiple sclerosis	5.8e-06	2.3e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCL2—multiple sclerosis	5.8e-06	2.3e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL2—multiple sclerosis	5.8e-06	2.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL2—multiple sclerosis	5.78e-06	2.29e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL5—multiple sclerosis	5.76e-06	2.29e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—APOE—multiple sclerosis	5.76e-06	2.29e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—IL6—multiple sclerosis	5.71e-06	2.27e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—STAT3—multiple sclerosis	5.7e-06	2.26e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1B—multiple sclerosis	5.68e-06	2.25e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL2—multiple sclerosis	5.66e-06	2.25e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL2—multiple sclerosis	5.65e-06	2.24e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—BCHE—multiple sclerosis	5.64e-06	2.24e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—POMC—multiple sclerosis	5.62e-06	2.23e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—POMC—multiple sclerosis	5.61e-06	2.23e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—TYK2—multiple sclerosis	5.57e-06	2.21e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—POMC—multiple sclerosis	5.54e-06	2.2e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCL2—multiple sclerosis	5.5e-06	2.18e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCL2—multiple sclerosis	5.49e-06	2.18e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MMP9—multiple sclerosis	5.49e-06	2.18e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—APOE—multiple sclerosis	5.47e-06	2.17e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—STAT3—multiple sclerosis	5.46e-06	2.17e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—IL6—multiple sclerosis	5.44e-06	2.16e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—STAT3—multiple sclerosis	5.41e-06	2.15e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—STAT3—multiple sclerosis	5.4e-06	2.14e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL2—multiple sclerosis	5.39e-06	2.14e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TYK2—multiple sclerosis	5.36e-06	2.13e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—STAT3—multiple sclerosis	5.36e-06	2.13e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MMP9—multiple sclerosis	5.35e-06	2.12e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SPP1—multiple sclerosis	5.33e-06	2.12e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CD80—multiple sclerosis	5.32e-06	2.11e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.3e-06	2.1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—MAPK1—multiple sclerosis	5.28e-06	2.1e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RRM1—multiple sclerosis	5.27e-06	2.09e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TYK2—multiple sclerosis	5.26e-06	2.09e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—STAT3—multiple sclerosis	5.26e-06	2.09e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IFNG—multiple sclerosis	5.22e-06	2.07e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CD80—multiple sclerosis	5.21e-06	2.07e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCR5—multiple sclerosis	5.19e-06	2.06e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—MAPK1—multiple sclerosis	5.18e-06	2.06e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TYK2—multiple sclerosis	5.14e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	5.11e-06	2.03e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MMP9—multiple sclerosis	5.1e-06	2.03e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—POMC—multiple sclerosis	5.07e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MYC—multiple sclerosis	5.07e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TGFB1—multiple sclerosis	5.06e-06	2.01e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	5.05e-06	2.01e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—ALB—multiple sclerosis	5.05e-06	2e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD4—multiple sclerosis	5.04e-06	2e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TYK2—multiple sclerosis	5e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—STAT3—multiple sclerosis	4.99e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IL6—multiple sclerosis	4.99e-06	1.98e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	4.98e-06	1.98e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—STAT3—multiple sclerosis	4.98e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MYC—multiple sclerosis	4.98e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—TGFB1—multiple sclerosis	4.97e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MAPK1—multiple sclerosis	4.96e-06	1.97e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—POMC—multiple sclerosis	4.95e-06	1.96e-05	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.94e-06	1.96e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	4.94e-06	1.96e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—MAPK1—multiple sclerosis	4.92e-06	1.95e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—BCHE—multiple sclerosis	4.91e-06	1.95e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—MAPK1—multiple sclerosis	4.91e-06	1.95e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL6—multiple sclerosis	4.9e-06	1.95e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MYC—multiple sclerosis	4.89e-06	1.94e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—TGFB1—multiple sclerosis	4.88e-06	1.94e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	4.88e-06	1.94e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MAPK1—multiple sclerosis	4.87e-06	1.93e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—STAT3—multiple sclerosis	4.86e-06	1.93e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCL2—multiple sclerosis	4.84e-06	1.92e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MAPK1—multiple sclerosis	4.78e-06	1.9e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—STAT3—multiple sclerosis	4.76e-06	1.89e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—STAT3—multiple sclerosis	4.75e-06	1.89e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—APOE—multiple sclerosis	4.72e-06	1.87e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—POMC—multiple sclerosis	4.7e-06	1.87e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—IL6—multiple sclerosis	4.68e-06	1.86e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1B—multiple sclerosis	4.65e-06	1.85e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CD4—multiple sclerosis	4.65e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—multiple sclerosis	4.64e-06	1.84e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL2—multiple sclerosis	4.64e-06	1.84e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—BCHE—multiple sclerosis	4.63e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—TGFB1—multiple sclerosis	4.63e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—multiple sclerosis	4.63e-06	1.84e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—ALB—multiple sclerosis	4.62e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—TGFB1—multiple sclerosis	4.62e-06	1.83e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.55e-06	1.81e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MAPK1—multiple sclerosis	4.54e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—STAT3—multiple sclerosis	4.53e-06	1.8e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	4.53e-06	1.8e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MAPK1—multiple sclerosis	4.53e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—IL6—multiple sclerosis	4.52e-06	1.8e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	4.52e-06	1.8e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	4.49e-06	1.78e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—STAT3—multiple sclerosis	4.49e-06	1.78e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL2—multiple sclerosis	4.46e-06	1.77e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	4.43e-06	1.76e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—MAPK1—multiple sclerosis	4.42e-06	1.75e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—multiple sclerosis	4.42e-06	1.75e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TGFB1—multiple sclerosis	4.41e-06	1.75e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TYK2—multiple sclerosis	4.39e-06	1.75e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL2—multiple sclerosis	4.38e-06	1.74e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—MAPK1—multiple sclerosis	4.33e-06	1.72e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MAPK1—multiple sclerosis	4.32e-06	1.72e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ALB—multiple sclerosis	4.28e-06	1.7e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CD80—multiple sclerosis	4.27e-06	1.69e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP9—multiple sclerosis	4.22e-06	1.68e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—multiple sclerosis	4.21e-06	1.67e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TGFB1—multiple sclerosis	4.2e-06	1.67e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—multiple sclerosis	4.17e-06	1.66e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TGFB1—multiple sclerosis	4.16e-06	1.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL2—multiple sclerosis	4.16e-06	1.65e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.15e-06	1.65e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	4.15e-06	1.65e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP9—multiple sclerosis	4.15e-06	1.65e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MAPK1—multiple sclerosis	4.12e-06	1.64e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MAPK1—multiple sclerosis	4.08e-06	1.62e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—POMC—multiple sclerosis	4.05e-06	1.61e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL6—multiple sclerosis	4.05e-06	1.61e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—multiple sclerosis	3.98e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL2—multiple sclerosis	3.97e-06	1.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—multiple sclerosis	3.93e-06	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	3.92e-06	1.56e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—BCHE—multiple sclerosis	3.92e-06	1.56e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—STAT3—multiple sclerosis	3.9e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—multiple sclerosis	3.81e-06	1.51e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—multiple sclerosis	3.78e-06	1.5e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—multiple sclerosis	3.77e-06	1.5e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STAT3—multiple sclerosis	3.75e-06	1.49e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—multiple sclerosis	3.74e-06	1.49e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	3.73e-06	1.48e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—multiple sclerosis	3.69e-06	1.46e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—multiple sclerosis	3.68e-06	1.46e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—multiple sclerosis	3.66e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TYK2—multiple sclerosis	3.6e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—multiple sclerosis	3.6e-06	1.43e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK1—multiple sclerosis	3.55e-06	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	3.53e-06	1.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—multiple sclerosis	3.5e-06	1.39e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—multiple sclerosis	3.49e-06	1.39e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	3.49e-06	1.39e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—multiple sclerosis	3.49e-06	1.38e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—multiple sclerosis	3.48e-06	1.38e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—multiple sclerosis	3.48e-06	1.38e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—multiple sclerosis	3.46e-06	1.37e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—multiple sclerosis	3.42e-06	1.36e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	3.42e-06	1.36e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK1—multiple sclerosis	3.41e-06	1.35e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	3.41e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—multiple sclerosis	3.4e-06	1.35e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOE—multiple sclerosis	3.39e-06	1.35e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	3.35e-06	1.33e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—multiple sclerosis	3.35e-06	1.33e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—multiple sclerosis	3.34e-06	1.33e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—multiple sclerosis	3.32e-06	1.32e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—multiple sclerosis	3.32e-06	1.32e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK1—multiple sclerosis	3.27e-06	1.3e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—multiple sclerosis	3.25e-06	1.29e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—multiple sclerosis	3.24e-06	1.29e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	3.24e-06	1.29e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	3.23e-06	1.28e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK1—multiple sclerosis	3.18e-06	1.26e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	3.17e-06	1.26e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—multiple sclerosis	3.17e-06	1.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	3.14e-06	1.25e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—multiple sclerosis	3.13e-06	1.24e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—multiple sclerosis	3.08e-06	1.22e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.03e-06	1.2e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—multiple sclerosis	3e-06	1.19e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOE—multiple sclerosis	2.96e-06	1.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	2.92e-06	1.16e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—POMC—multiple sclerosis	2.92e-06	1.16e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	2.91e-06	1.16e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—multiple sclerosis	2.86e-06	1.14e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	2.86e-06	1.13e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—multiple sclerosis	2.85e-06	1.13e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—multiple sclerosis	2.84e-06	1.13e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK1—multiple sclerosis	2.8e-06	1.11e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOE—multiple sclerosis	2.79e-06	1.11e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—multiple sclerosis	2.72e-06	1.08e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—multiple sclerosis	2.66e-06	1.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—multiple sclerosis	2.62e-06	1.04e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—multiple sclerosis	2.57e-06	1.02e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—POMC—multiple sclerosis	2.54e-06	1.01e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—multiple sclerosis	2.52e-06	1e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—multiple sclerosis	2.52e-06	9.99e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—multiple sclerosis	2.44e-06	9.7e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	2.44e-06	9.68e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—POMC—multiple sclerosis	2.39e-06	9.5e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOE—multiple sclerosis	2.36e-06	9.37e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—multiple sclerosis	2.34e-06	9.31e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	2.34e-06	9.28e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—multiple sclerosis	2.32e-06	9.19e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	2.29e-06	9.1e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	2.2e-06	8.72e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—multiple sclerosis	2.18e-06	8.66e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—multiple sclerosis	2.15e-06	8.53e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—POMC—multiple sclerosis	2.03e-06	8.05e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—multiple sclerosis	1.85e-06	7.34e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOE—multiple sclerosis	1.82e-06	7.23e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—multiple sclerosis	1.76e-06	7e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—POMC—multiple sclerosis	1.56e-06	6.21e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.43e-06	5.66e-06	CbGpPWpGaD
